Q1 FY26 Earnings Results
Q1 FY26 earnings, Apr–Jun 2025: 5,166 Indian listed companies have reported; median profit growth is +4.8% on last year, and 0 of 1 companies with analyst estimates beat them. Quarter ended 30 Jun 2025.
Reported
5,166
companies
Profit breadth
53% / 44%
grew / declined · 3,553 comparable
Median sales YoY
+6.8%
across all reporters
Median profit YoY
+4.8%
across all reporters
Beat / missed
0 / 1
of 1 covered
Strongest / weakest
Insurance +28.8%
Capital Markets −18.4%
median profit growth, 10+ reporters
Clear filters 201–234 of 234
| Company | Revenue (₹ Cr) | Profit (₹ Cr) | Per share | 8Q profit | |||||
|---|---|---|---|---|---|---|---|---|---|
| Symbol | Sector | Reported | YoY | QoQ | Reported | YoY | EPS | vs consensus | Trend |
 UNJHAFORMULATIONSLTD | Healthcare | 4 | down−8.1% | up+48.8% | 0 | down−44.3% | 0.87 | No estimate | |
 ZENITHHEALTHCARELTD | Healthcare | 3 | up+22.6% | down−8.2% | 0 | down−112.5% | 0.00 | No estimate | |
 ACHYUTHEALTHCARELTD | Healthcare | 3 | n/a | up+235.9% | 0 | n/a | 0.00 | No estimate | |
 DECIPHERLABSLTD | Healthcare | 3 | down−60.8% | down−16.6% | −3 | down−461.1% | −3.40 | No estimate | |
| Sangam Health Care Products Ltd | Healthcare | 3 | down−16.8% | up+9.3% | 0 | up+25.0% | 0.07 | No estimate | |
 AUROLABORATORIESLTD | Healthcare | 3 | down−51.6% | down−62.6% | 0 | down−114.7% | −0.18 | No estimate | |
 MEDINOVADIAGNOSTICSERVICELTD Medinova Diagnostic Services Ltd | Healthcare | 3 | up+9.2% | up+8.4% | 1 | up+57.1% | 0.66 | No estimate | |
| Medinova Diagnostic Services Ltd | Healthcare | 3 | up+9.2% | up+8.4% | 1 | up+57.1% | 0.66 | No estimate | |
 GUJINJECLTD Gujarat Inject (Kerala) Ltd | Healthcare | 2 | down−20.7% | down−42.9% | 0 | down−41.7% | 0.00 | No estimate | |
 SUVEN Suven Life Sciences Ltd | Healthcare | 2 | up+100.0% | up+100.0% | −52 | n/a | −2.36 | No estimate | |
 PARMAXPHARMALTD | Healthcare | 2 | down−75.2% | down−59.8% | −1 | down−7,700.0% | −2.03 | No estimate | |
 AMBALALSA Ambalal Sarabhai Enterprises Ltd | Healthcare | 2 | up+43.9% | down−5.2% | 7 | up+1,395.7% | 0.90 | No estimate | |
 COLINZLABORATORIESLTD | Healthcare | 2 | down−10.3% | up+8.3% | 0 | down−14.3% | 0.48 | No estimate | |
 VISTAPHARMACEUTICALSLTD | Healthcare | 2 | down−15.6% | down−52.9% | −1 | n/a | −0.21 | No estimate | |
 SHREEGANESHBIOTECHINDIALTD | Healthcare | 1 | down−61.2% | down−54.2% | 0 | up+37.5% | 0.01 | No estimate | |
 DESHRAKSHAKAUSHDHALAYALTD | Healthcare | 1 | up+20.4% | down−70.4% | 0 | up+11.1% | 0.23 | No estimate | |
| VENMAXDRUGSPHARMACEUTICALSLTD Venmax Drugs & Pharmaceuticals Ltd | Healthcare | 1 | up+1,110.0% | up+266.7% | 0 | up+300.0% | 0.08 | No estimate | |
 Span Divergent Ltd | Healthcare | 1 | down−71.2% | up+94.5% | 0 | n/a | −0.18 | No estimate | |
 GENOMICVALLEYBIOTECHLTD | Healthcare | 0 | down−43.8% | down−65.4% | 0 | down−84.6% | 0.07 | No estimate | |
 ORTINGLOBE Ortin Global Ltd | Healthcare | 0 | down−61.9% | down−11.1% | 0 | n/a | −0.22 | No estimate | |
 SHYAMAINFOLTD Shyama Computronics and Services Ltd | Healthcare | 0 | up+16.7% | 0.0% | 0 | 0.0% | 0.01 | No estimate | |
 TRANSCHEMLTD | Healthcare | 0 | n/a | down−100.0% | 1 | down−40.4% | 0.81 | No estimate | |
 CHEMOPHARMALABORATORIESLTD Starsource Multitrade Ltd | Healthcare | 0 | n/a | n/a | −12 | down−4,824.0% | −78.73 | No estimate | |
 TRIOCHEMPRODUCTSLTD | Healthcare | 0 | n/a | n/a | 0 | n/a | −1.22 | No estimate | |
| GENESISIBRCINDIALTD CCME Global Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.09 | No estimate | |
 MEDICAPQ Medi Caps Ltd | Healthcare | 0 | down−100.0% | down−100.0% | 0 | n/a | −0.32 | No estimate | |
 BACILPHARMALTD | Healthcare | 0 | n/a | n/a | 1 | n/a | 0.47 | No estimate | |
 KAMRONLABORATORIESLTD Adline Chem Lab Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.09 | No estimate | |
| REKVINALABORATORIESLTD Rekvina Labs Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.03 | No estimate | |
| RAYMEDLABSLTD Cresanto Global Limited | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.21 | No estimate | |
| MPS Pharmaa Ltd | Healthcare | 0 | n/a | n/a | 0 | n/a | −0.12 | No estimate | |
 TAKE Take Ltd | Healthcare | 0 | n/a | n/a | −1 | n/a | −0.06 | No estimate | |
 Transchem Ltd | Healthcare | 0 | n/a | down−100.0% | 1 | down−40.4% | 0.81 | No estimate | |
| Harleystreet Pharmaceuticals Ltd(merged) | Healthcare | — | n/a | n/a | 157 | up+19.8% | 5.00 | No estimate | |
About Q1 FY26 earnings data
When are Q1 FY26 results announced?
Q1 FY26 covers the Apr–Jun 2025 quarter. Indian listed companies have up to 45 days after a quarter closes to file their results — 60 days for the January–March quarter — so results arrive in a wave over the weeks that follow rather than all at once. A quarter that has only just ended will look sparse and fill in.
Why do some Q1 FY26 growth figures show "n/a" instead of a percentage?
Growth is left blank whenever the comparison period was not profitable. A percentage change measured from a loss is arithmetic without meaning — a swing from a ₹10 crore loss to a ₹10 crore profit is not "200% growth", and publishing it as such would flatter the company. The reported figures for both periods are still shown, so the change is there to read directly.
Does the beat/miss verdict cover every company?
No, and the denominator matters. An analyst consensus existed for 1 of the 5,166 companies that reported Q1 FY26 — 0.0%. Beat, missed and in-line describe only those. Every other company is marked "no estimate" rather than being counted as in line, because nobody forecast it. Revenue and profit growth, by contrast, cover every company in the table.
What counts as an in-line result rather than a beat or a miss?
Reported earnings per share within ±2% of the consensus estimate. The band is set there because a tighter one classifies rounding as news, and a wider one swallows surprises that genuinely moved a stock.
Are the figures consolidated or standalone?
Consolidated where a company reports on that basis, standalone otherwise, with all money in ₹ crore. Figures are as filed by the company with the exchanges (NSE/BSE); they are not restated or adjusted.
What does the 8-quarter trend line show?
Quarterly net profit for the last eight quarters, oldest on the left, always ending on the quarter shown in the row. Two years covers both the seasonal shape of the business and its direction. The line breaks where a quarter is missing rather than drawing across the gap, so a break is a real absence of data and not a reported collapse.
How do I find only the companies that beat estimates in Q1 FY26?
Use the Result filter above the table and choose Beat, or sort by EPS surprise to rank every covered company by how far it landed from consensus. Both are reflected in the page URL, so a filtered view can be bookmarked or shared.
Figures are as reported by companies in their quarterly filings to the exchanges (NSE/BSE), in ₹ crore. Consolidated results are shown where a company reports them, otherwise standalone. Year-on-year and quarter-on-quarter growth is omitted where the comparison period was loss-making, since a percentage change from a negative base is not meaningful. Analyst consensus is an estimate, not a forecast of outcome.